Scancell Holdings Plc Block Listing Application to AIM (3416W)
17 April 2023 - 4:00PM
UK Regulatory
TIDMSCLP
RNS Number : 3416W
Scancell Holdings Plc
17 April 2023
17 April 2023
Scancell Holdings plc
("Scancell" or the "Company")
Block Listing Application to AIM
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies, announces an application has been made to AIM for
a block listing of 2,880,000 ordinary shares of 0.1 pence each in
the Company ("Ordinary Shares"). This will be used to facilitate
the admission of Ordinary Shares to trading following the exercise
of options granted on the basis of one share per share option.
The Ordinary Shares will be issued from time to time pursuant to
the Company's existing share options plan for Richard Goodfellow
for outstanding options already issued but not yet exercised by
Richard Goodfellow. New Ordinary Shares issued following option
exercises and admitted to trading under the block admission will
rank pari passu in all respects with the existing Ordinary
Shares.
The block listing is expected to become effective on 20 April
2023. The Company will make six-monthly announcements of the
utilisation of the block admission, in line with its obligations
under AIM Rule 29.
At the time of this announcement, Scancell has 818,403,461
Ordinary Shares in issue. This figure may be used by shareholders
in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change in their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr Jean-Michel Cosséry, Non-Executive
Chairman
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated
Adviser and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Rob Winder/Alex Davis
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope(R) and
ImmunoBody(R) for vaccines and GlyMab(R) and AvidiMab(R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope(R) and
ImmunoBody(R) ) this includes citrullination and homocitrullination
of proteins, whereas its mAb portfolio targets glycans or sugars
that are added onto proteins and / or lipids (GlyMab(R) ) or
enhances the potency of antibodies and their ability to directly
kill tumour cells (AvidiMab(R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSBLGDSCSBDGXL
(END) Dow Jones Newswires
April 17, 2023 02:00 ET (06:00 GMT)
Scancell (AQSE:SCLP.GB)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (AQSE:SCLP.GB)
Historical Stock Chart
From May 2023 to May 2024